Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study
Jean Marc Steens, Didier Scherrer, Paul Gineste, P. Noel Barrett, Supparatpino Khuanchai, Ratanasuwan Winai, Kiat Ruxrungtham, Jamal Tazi, Robert Murphy, Hartmut Ehrlich*
Dive into the research topics of 'Safety, pharmacokinetics, and antiviral activity of a novel HIV antiviral, ABX464, in treatment-naive HIV-infected subjects in a phase 2 randomized, controlled study'. Together they form a unique fingerprint.